CpG 9328
Latest Information Update: 27 May 2003
At a glance
- Originator Coley Pharmaceutical Group
- Class Antiallergics; Antiasthmatics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Allergic rhinitis; Asthma
Most Recent Events
- 27 May 2003 No development reported - Phase-II for Allergic rhinitis in USA (unspecified route)
- 27 May 2003 No development reported - Phase-II for Asthma in USA (unspecified route)
- 20 Aug 2001 Phase-II clinical trials for Allergic rhinitis in USA (Unknown route)